Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 10/2019

Open Access 01-10-2019 | Septicemia | Study Protocol

Exploration of Different Rehabilitation Routes for Sepsis Survivors with Monitoring of Health Status and Quality of Life: RehaSep Trial Protocol

Authors: Barbara Wójcik, Jerzy Superata, H. Bryant Nguyen, Zbigniew Szyguła

Published in: Advances in Therapy | Issue 10/2019

Login to get access

Abstract

Introduction

This project addresses the important problem of sepsis sequelae resulting in frequent hospital readmissions and higher mortality rate in the post-discharge period. However, neither specific diagnostic methods nor standards for rehabilitation of sepsis patients have been introduced yet. The aim of this study is to evaluate the effectiveness of two different multiparameter-monitored rehabilitation treatments in order to improve the health status and quality of life of sepsis survivors.

Methods

Decades of failed randomized controlled trials involving sepsis patients strongly suggest the need for a paradigm change. Therefore, we designed a prospective, interventional, controlled, pragmatic, patient-centred trial based on the principles of personalized medicine. Sixty post-sepsis patients after hospital discharge will be individually assigned to a control group (without intervention) and two groups with 3-month diagnostically monitored rehabilitation programs based either on the recumbent cycloergometer training or on the experimental hyperbaric oxygen therapy. In all of the patients a wide range of physiological (spirometry, ECG/cycloergometer exercise test), haematological (microscopy) and biochemical (blood tests) parameters will be assessed at hospital discharge and during subsequent 3 months in order to monitor changes of their physical capacity, immunity and degree of post-sepsis organ damage/recovery. For quality of life monitoring a novel tool—“Life After Sepsis Survey”—will be applied.

Planned Outcomes

A set of composite quantitative indices resulting from laboratory measurement data combined with the quality of life questionnaire data will constitute the primary outcomes whereas mortality rate and hospital readmission number will be counted as the secondary outcomes.

Conclusions

Critical analysis of past trials prompted us to implement multiple improvements in tools and procedures. The results of this trial will contribute to the development of rehabilitation therapy addressing not only weakness but also organ damage problems of sepsis survivors.

Trial Registration

ANZCTR (http://​www.​anzctr.​org.​au): ACTRN12618000347268, U1111-1210-6110.

Funding

This research was funded by the National Science Center, Poland.
Literature
1.
2.
Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global sepsis incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259–72.PubMedCrossRef
3.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–10.PubMedPubMedCentralCrossRef
4.
5.
Oeschger T, McCloskey D, Kopparthy V, Singh A, Ericson D. Point of care technologies for sepsis diagnosis and treatment. Lab Chip. 2019;19(5):728–37.PubMedCrossRefPubMedCentral
6.
7.
8.
Meyer N, Harhay MO, Small DS, et al. Temporal trends in incidence, sepsis-related mortality, and hospital-based acute care after sepsis. Crit Care Med. 2018;46(3):354–60.PubMedPubMedCentralCrossRef
9.
Goodwin AJ, Liu V, Ford DW. Hospital readmissions in sepsis survivors: are they preventable? Ann Am Thorac Soc. 2017;14(2):170–1.PubMed
10.
Curthbertson BH, Elders A, Hall S, et al. Mortality and quality of life in the five years after severe sepsis. Crit Care. 2013;17(2):1–7.
11.
Desai SV, Law TJ, Needham DJ. Long-term complications of critical care. Crit Care Med. 2011;39:371–9.PubMedCrossRef
12.
Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787–94.PubMedPubMedCentralCrossRef
13.
Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10:931–41.PubMedCrossRef
14.
Guirgis FW, Khadpe JD, Kuntz GM, Wears RL, Kalynych CJ, Jones AE. Persistent organ dysfunction after severe sepsis: a systematic review. J Crit Care. 2014;29(3):320–6.PubMedCrossRef
15.
Zimmer A, Rothaug J, Mescha S, Reinhart K, Meissner W. Chronic pain after surviving sepsis: A-909. Eur J Anaesthesiol. 2006;23:235–6.CrossRef
16.
Myhren H, Ekeberg O, Tøien K, Karlsson S, Stokland O. Posttraumatic stress, anxiety and depression symptoms in patients during the first year post intensive care unit discharge. Crit Care. 2010;14(1):R14.PubMedPubMedCentralCrossRef
17.
Yende S, Austin S, Rhodes A, et al. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit Care Med. 2016;44(8):1461–7.PubMedPubMedCentralCrossRef
18.
Connolly B, Salisbury L, O’Neill B, et al. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness. Cochrane Database Syst Rev. 2015;6:1–4.
19.
Mira JC, Brakenridge SC, Moldawer LL, Moore FA. Persistent inflammation, immunosuppression and catabolism syndrome. Crit Care Clin. 2017;33(2):245–58.PubMedPubMedCentralCrossRef
20.
Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA. 2009;106:8665–80.PubMedCrossRefPubMedCentral
21.
Francescomarino S, Sciartilli A, Valerio V, Di Baldassarre A, Gallina S. The effect of physical exercise on endothelial function. Sports Med. 2009;39(10):797–812.PubMedCrossRef
22.
Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011;11(9):607–15.PubMedCrossRef
23.
de Araújo CC, Silva JD, Samary CS, et al. Regular and moderate exercise before experimental sepsis reduces the risk of lung and distal organ injury. J Appl Physiol. 2012;112:1206–14.PubMedCrossRef
24.
Lee CJ, Peng TC, Hsu BG, Harn HJ, Chao YF, Lee RP. Lack of exercise decreases survival and increases organ damage after hemorrhagic shock in rats. Biol Res Nurs. 2010;12:198–205.PubMedCrossRef
25.
26.
Almzaiel AJ, Billington R, Smerdon G, Moody AJ. Effects of hyperbaric oxygen treatment on antimicrobial function and apoptosis of differentiated HL-60 (neutrophil-like) cells. Life Sci. 2013;93(2–3):125–31.PubMedCrossRef
27.
Mortensen CR. Hyperbaric oxygen therapy. Curr Anaest Crit Care. 2008;19:333–7.CrossRef
28.
Weaver LK. Hyperbaric medicine for the hospital-based physician. Hosp Pract. 2012;40(3):88–101.CrossRef
29.
Wright SE, Thomas K, Watson G, et al. Intensive versus standard physical rehabilitation therapy in the critically ill (EPICC): a multicentre, parallel-group, randomised controlled trial. Thorax. 2018;73(3):213–21.PubMedCrossRef
30.
Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J. 2005;26(1):153–61.PubMedCrossRef
31.
Huang CY, Daniels R, Lembo A, et al. Life after sepsis: an international survey of survivors to understand the post-sepsis syndrome. Int J Qual Health Care. 2018;31(3):191–8.CrossRef
32.
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018.
33.
Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2016.CrossRef
34.
35.
36.
Paratz DJ, Kenardy J, Mitchell G, et al. IMPOSE (IMProving Outcomes after Sepsis)—the effect of a multidisciplinary follow-up service on health-related quality of life in patients postsepsis syndromes—a double-blinded randomized controlled trial: protocol. BMJ Open. 2014;4:1–5.CrossRef
37.
Reinhart K, Brunkhorst FM, Bone HG, et al. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci. 2010;8:26–7.
38.
Prescott HC, Costa DK. Improving long-term outcomes after sepsis. Crit Care Clin. 2018;34(1):175–88.PubMedCrossRef
39.
Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2013;13(2):217–24.
40.
Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med. 2010;38(10):S534–8.PubMedCrossRef
41.
Vincent JL. Improved survival in critically ill patients: are large RCTs more useful than personalized medicine? No. Intensive Care Med. 2016;42(11):1778–80.PubMedCrossRef
42.
43.
Major ME, Kwakman R, Kho ME, et al. Surviving critical illness: what is next? An expert consensus statement on physical rehabilitation after hospital discharge. Crit Care. 2016;20(1):354.PubMedPubMedCentralCrossRef
44.
Loftus TJ, Mira JC, Ozrazgat-Baslanti T. Sepsis and Critical Illness Research Center investigators: protocols and standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients. BMJ Open. 2017;7(7):e015136.PubMedPubMedCentralCrossRef
45.
Metadata
Title
Exploration of Different Rehabilitation Routes for Sepsis Survivors with Monitoring of Health Status and Quality of Life: RehaSep Trial Protocol
Authors
Barbara Wójcik
Jerzy Superata
H. Bryant Nguyen
Zbigniew Szyguła
Publication date
01-10-2019
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 10/2019
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01047-9

Other articles of this Issue 10/2019

Advances in Therapy 10/2019 Go to the issue

Original Research

Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients

Original Research

Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Commentary

Oral Corticosteroid Use for the Treatment of Chronic Eosinophilic Disease: A Patient’s and His Physician’s Experience

Original Research

Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis

Original Research

Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia

Original Research

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits